NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage pharmaceutical company developing treatments for severe depression, suicidal ideation, chronic pain, and PTSD. The company’s work centers on two experimental drugs: NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral combination pill designed to maintain the antidepressant effects of ketamine over time.
What NRx Pharmaceuticals Does
NRx focuses on psychiatric conditions where existing treatments fall short, particularly bipolar depression with suicidal thoughts. Their approach targets two receptor systems in the brain: NMDA receptors, which play a role in mood regulation and neural signaling, and serotonin receptors involved in emotional processing. By modulating both systems, the company aims to produce rapid and sustained relief from severe depressive episodes.
The company’s pipeline is built around a two-step treatment model. First, NRX-100 (ketamine given intravenously) stabilizes someone in an acute suicidal crisis. Then NRX-101, taken as a daily oral capsule, is intended to maintain that improvement without requiring repeated ketamine infusions.
NRX-100: Ketamine for Suicidal Crises
NRX-100 is a preservative-free formulation of intravenous ketamine designed specifically for people experiencing suicidal ideation alongside depression, including bipolar depression. Ketamine itself is not new. It has been used as an anesthetic for decades and has gained attention in psychiatry for its ability to reduce suicidal thoughts within hours rather than the weeks most antidepressants require. What NRx has done is develop a cleaner formulation (free of the preservatives found in standard ketamine vials) and pursue FDA approval for this specific psychiatric use.
The FDA granted NRX-100 Fast Track designation, a status that speeds up the review process for drugs addressing serious conditions with unmet medical needs. NRx has been compiling a New Drug Application that includes real-world data from more than 60,000 patients treated with intravenous ketamine for depression, compared against roughly 6,000 patients treated with intranasal esketamine (the only currently approved ketamine-related treatment for depression). The company expects to complete this application by late 2025.
Separately, NRx has filed for approval of a generic version of its preservative-free ketamine under the brand name KETAFREE, with an expected FDA review target date in the second quarter of 2026.
NRX-101: An Oral Follow-Up Treatment
NRX-101 combines two existing compounds into a single capsule. One is D-cycloserine, a partial activator of NMDA receptors that appears to extend the antidepressant effects ketamine triggers. The other is lurasidone, an antipsychotic already approved for bipolar depression. The idea is that after a patient responds to an initial ketamine infusion, NRX-101 can keep that response going through a daily pill rather than repeated IV sessions.
Preclinical research has shown that D-cycloserine does not cause the neurotoxic effects sometimes associated with repeated ketamine use, which is a meaningful distinction. If the combination works as intended, it could offer a practical path forward for people who respond well to ketamine but need something sustainable for longer-term management.
NRX-101 has received Breakthrough Therapy Designation from the FDA, a classification reserved for drugs that show substantial improvement over existing treatments in early clinical evidence. A confirmatory Phase 3 trial, this time testing NRX-101’s ability to boost the effects of transcranial magnetic stimulation (TMS, a non-drug brain stimulation therapy), is planned for early 2026.
Conditions NRx Is Targeting
The company’s primary focus is bipolar depression with suicidality, a condition that is notoriously difficult to treat. Standard antidepressants can trigger manic episodes in people with bipolar disorder, and many existing medications take weeks to show benefit. For someone in a suicidal crisis, that delay is dangerous. NRx’s two-drug approach attempts to solve both the speed problem (with ketamine) and the sustainability problem (with NRX-101).
Beyond depression and suicidality, NRx lists chronic pain and PTSD as therapeutic targets. Both conditions involve NMDA receptor activity, which is the biological pathway the company’s drugs are designed to influence. These indications are earlier in development than the depression and suicidality programs.
Where NRx Stands Now
NRx is a publicly traded company on the NASDAQ exchange under the ticker NRXP. It remains in the clinical and regulatory stage, meaning none of its products are commercially available yet. The nearest milestones include completing the NRX-100 New Drug Application in late 2025, the KETAFREE generic review date in mid-2026, and the Phase 3 trial for NRX-101 launching in early 2026.
As a clinical-stage biotech, NRx carries the typical financial profile of a company that spends heavily on research and regulatory filings without product revenue. Its stock price reflects the speculative nature of drug development, where a single FDA decision or trial result can shift the company’s trajectory significantly.